Finance
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Shares of Axsome Therapeutics (NASDAQ: AXSM) have been on a tear, and that just accelerated today. After soaring more than 20% last month, shares of the biopharmaceutical company jumped another 11.1% today, as of 3:10 p.m. ET.
Investors knew the company had just received a new approval from the Food and Drug Administration (FDA) last week. Still, today’s first-quarter update provided even more confidence in the company’s future potential.
Image source: The Motley Fool.
Investors think a new addition to the biotech’s pipeline could be the next catalyst.
Shares of Axsome Therapeutics (AXSM +8.47%) have been on a tear, and that just accelerated today. After soaring more than 20% last month, shares of the biopharmaceutical company jumped another 11.1% today, as of 3:10 p.m. ET.
Investors knew the company had just received a new approval from the Food and Drug Administration (FDA) last week. Still, today’s first-quarter update provided even more confidence in the company’s future potential.
Image source: The Motley Fool.
A growing pipeline
Some big news was already built into Axsome stock. That’s the reason shares have been on a tear in recent weeks, hitting new highs. Most recently, its biggest commercial drug was additionally approved by the FDA for the treatment of agitation related to dementia in patients with Alzheimer’s disease.
Over 5 million Americans could benefit from Axsome’s Auvelity in this regard. Auvelity will be the first with “clean-label status” for this application, and management said the commercial launch is on track for next month.
Axsome Therapeutics
Today’s Change
(8.47%) $17.49
Current Price
$224.02
Today’s earnings release brought more good news for biotech investors, too. Last month, Axsome acquired the exclusive global rights to the oral inhibitor balipodect from Takeda Pharmaceuticals. Now dubbed AXS-20, Axsome continues to develop the treatment. In its conference call for investors, management said it plans to set the stage for phase III trials of AXS-20 in Schizophrenia later this year.
That’s a short timeline for potential phase III results, and the stock is hitting another new record high today on the growing strength of Axsome’s pipeline.